Transgene, a leader in the development of virus-based cancer immunotherapies, and ProBioGen, a premier contract development and manufacturing organization (CDMO), announced today a significant expansion of their ongoing strategic partnership. Through a newly finalized license agreement, Transgene will gain expanded access to ProBioGen’s proprietary AGE1.CR.pIX suspension cell line, a move designed to bolster Transgene’s manufacturing infrastructure as its pipeline of therapeutic candidates moves closer to late-stage clinical trials.
The expansion of this partnership serves a critical purpose: securing a scalable and consistent manufacturing platform for complex viral vectors. By integrating the AGE1.CR.pIX system, Transgene aims to address the common bottlenecks associated with clinical-scale production, including process variability and yield inefficiencies.
Dr. Alessandro Riva, Chairman and CEO of Transgene, highlighted the strategic importance of this advancement. “We are pleased to expand the scope of our activities with ProBioGen,” said Dr. Riva. “This additional license reflects our confidence in the technology to prepare for future clinical needs at scale, ensuring our manufacturing capabilities are as robust as our scientific programs.”
At the heart of the agreement is the AGE1.CR.pIX platform, which has gained industry recognition for its ability to provide a stable, reproducible environment for viral vector generation. Unlike traditional substrate methods that can introduce variability, the ProBioGen platform utilizes a continuous cell line qualified as a GMP (Good Manufacturing Practice) master cell bank. Furthermore, it is cultivated in a chemically defined, animal-component-free medium, eliminating the risks of contamination and batch-to-batch inconsistency that often complicate the transition from laboratory settings to commercial production.
Dr. Volker Sandig, Chief Scientific Officer at ProBioGen, emphasized that this technological foundation allows biopharma companies to streamline their development workflows. “A continuous cell line… means every batch begins from the same fully characterized starting material,” Dr. Sandig explained. “That is the foundation of a process that is reproducible, scalable and straightforward to transfer — and it lets our partners focus on the virus-product rather than the cell substrate.”
For Transgene, this development is a clear signal that the company is proactively readying its supply chain for the demands of large-scale clinical trials. By leveraging ProBioGen’s specialized manufacturing technology, the company expects to see improvements in overall productivity and cost-effectiveness. As Transgene continues to advance its portfolio of immunotherapy treatments, this alliance provides the manufacturing stability necessary to ensure that its novel cancer therapies can be produced reliably and efficiently. The expanded license marks a milestone in the two companies’ relationship, underscoring a shared commitment to accelerating the production of high-quality biologics to meet the urgent needs of cancer patients worldwide.
Disclaimer: This content is auto-generated for informational purposes only.
Source: Read Original News
